

AMENDMENTS TO THE CLAIMS

1-4. (canceled)

5. (currently amended) A method of inhibiting intraocular neovascularization in an individual having age-related macular degeneration ~~an ocular disease~~, comprising the step of:

administering to the eye of said individual a pharmacologically effective dose of a lentiviral vector comprising a therapeutic gene that inhibits intraocular neovascularization, wherein said therapeutic gene encodes a fusion protein of Mig (monokine-induced by interferon-gamma) and IP10 (interferon-alpha inducible protein 10).

6-9. (canceled)

10. (currently amended) The method of claim 5, wherein said lentiviral vector is administered in a dosage of from about 10^6 to 10^9 transducing particles into the capsular, ~~vitreal~~ vitreous or sub-retinal space.